Hepatotoxicity during anti tuberculosis chemotherapy

  • Authors

    • R. Djebaili Department of Pulmonary diseases, faculty of medicine, Batna2 university
    • O. Guerza Intensive care anesthesia, faculty of medicine, Batna2 university -Batna- Algeria
    • A. Romane Tuberculosis and Respiratory Diseases Control Department of Batna
    2024-08-04
    https://doi.org/10.14419/g3wyqn50
  • Tuberculosis; Adverse Reactions; Anti-Tuberculosis Treatment; Cytolysis; Cholestasis; Isoniazid.

  • Abstract

    Introduction: Despite their efficacy in tuberculosis treatment, side-effects of anti-tuberculosis drugs can be serious or fatal. The aim of our study is to determine the prevalence of hepatic toxicities associated with anti-tuberculosis drugs, their evolutionary aspects, and their management.

    Patients and methods: A retrospective descriptive study including 82 patients having received antituberculosis treatment and who pre-sented a hepatic cytolysis, collected at the Tuberculosis and Respiratory Diseases Control Department of Batna- Algeria between 2016 -2023. The aim of our study is to determine the prevalence of hepatic toxicities of anti-tuberculosis drugs, their evolutionary aspects, as well as the modalities of their management.

    Results: 82 out of 119 (69.23%) patients who experienced other adverse events were recruited between 2016 and 2023, aged between 15 and 86 years, with an average age of 43 years and a female predominance of 63.41%. Cholestasis syndrome was noted in 21 patients and frank jaundice in 4. Cytolysis was discovered incidentally in 68% of patients; it was mild in 56 (68.29%), moderate in 16 (19.51%) and severe in 10 (12.19%). Transaminase disturbance appeared within 3 months in 76.82% of cases, whereas a delay of 30 days was noted for normalisation of the liver function test after cessation of anti-tuberculosis treatment in 62 (76%) patients. Definitive discontin-uation of isoniazid (INH) was adopted in 17 (20%) patients, while a reduction in the doses of rifampicin and isoniazid was decided in 65 (80%) patients.

    Conclusion: Drug-induced hepatitis is one of the major side-effects of anti-tuberculosis drugs and can be lethal, hence the need for rapid and appropriate management. Healthcare professionals need to be informed about the types of suspected adverse drug reactions, they should report in subjects at risk.

  • References

    1. Aouam K, Chaabane A, Loussaïef C, Ben Romdhane F, N-A Boughattas, Chakroun M. Adverse effects of antitubercular drugs: epide-miology, mechanisms, and patient management, Medicine & Infectious Diseases. Volume 37, Issue 5, 2007,253-261. https://doi.org/10.1016/j.medmal.2006.12.006.
    2. Kwas H, Guermazi E, Zendah I, Khattab A, Khouaja I, Ghédira H. The major side effects of anti-tuberculosis drugs, Journal of Respir-atory Diseases vol 33 P. A148-A149 - janvier 2016 https://doi.org/10.1016/j.rmr.2015.10.283.
    3. Blumberg H.M, Burman W.J, Chaisson R.E, Daley C.L, Etkind S.C, Friedman L.N, et al. American Thoracic Society/Centers for Dis-ease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis Am. J. Respir. Crit. Care Med., 167 (4) (2003), pp. 603-662 https://doi.org/10.1164/rccm.167.4.603.
    4. Shakya R, Rao B.S, Shrestha B. Incidence of hepatotoxicity due to antitubercular medicines and assessment of risk factors Ann Phar-macother 2004 Jun;38(6):1074-9. https://doi.org/10.1345/aph.1D525.
    5. Pande J.N, Singh S.P, Khilnani G.C, Khilnani S, Tandon R.K. Risk factors for hepatotoxicity from antituberculosis drugs: à case-control study Thorax, 51 (1996), pp. 132-136, https://doi.org/10.1136/thx.51.2.132.
    6. Sharma S.K. Antituberculosis drugs and hepatotoxicity Infect. Genet. Evol., 4 (2004), pp. 167-170. https://doi.org/10.1016/S1567-1348(04)00012-7.
    7. Giroud J.P, Mathé G, Meyniel G et al. Clinical pharmacology. Basics of therapeutics. 2e edition (1988)
    8. British Thoracic Society Chemotherapy and management of tuberculosis in the United Kingdom: recommendations 1998 Thorax, 53 (1998), pp. 536-548. https://doi.org/10.1136/thx.53.7.536.
    9. Mitchell I, Wendon J, Fitt S. R. Williams. Antituberculosis therapy and acute liver failure. Lancet, 345 (1995), pp. 555-556. https://doi.org/10.1016/S0140-6736(95)90468-9.
    10. Mallat A. Drug-induced hepatitis: diagnosis and management Gastroenterol. Clin. Biol., 23 (1999), p. 906
    11. Rajani Shakya, B Subba Rao, Bhawana Shrestha. Incidence of hepatotoxicity due to antitubercular medicines and assessment of risk factors. 2004 Jun ;38(6) :1074-9. https://doi.org/10.1345/aph.1D525.
    12. Algerian manual on tuberculosis control for medical staff, 2011 edition.
    13. Metushi IG, Cai P, Zhu X, Nakagawa T, Uetrecht JP. A fresh look at the mechanism of isoniazid-induced hepatotoxicity. Clin Pharma-col Ther. 2011 ;89 :911–4. https://doi.org/10.1038/clpt.2010.355.
    14. Meng X, Maggs JL, Usui T, et al. Auto-oxidation of isoniazid leads to isonicotinic-lysine adducts on human serum albumin. Chem Res Toxicol. 2015; 28:51-8. https://doi.org/10.1021/tx500285k.
    15. Sarma G R, Immanuel C, Kailasam S, Narayana A S, Venkatesan P. Rifampin-induced release of hydrazine from isoniazid. A possible cause of hepatitis during treatment of tuberculosis with regimens containing isoniazid and rifampin Am Rev Respir Dis 1986 Jun ;133(6): 1072-5.
    16. Jenner J.P. Isoniazid-related hepatotoxicity: a study of the effect of rifampicin administration on the metabolism of acetylisoniazid in man Tubercle, 70 (1989), p. 93. https://doi.org/10.1016/0041-3879(89)90033-0.
    17. Duroux P. Monitoring and accidents during anti-tuberculosis chemotherapy. Rev Prat 1979 ;29 :2681- 9.
    18. Perriot J, Chambonnet E, Eschalier A, Adverse effects of anti-tuberculosis drugs; management; Journal of Respiratory Diseases (2011) 28, 542—555. https://doi.org/10.1016/j.rmr.2010.10.034.

  • Downloads

  • How to Cite

    Djebaili, R., Guerza, O., & Romane, A. (2024). Hepatotoxicity during anti tuberculosis chemotherapy. International Journal of Medicine, 12(2), 38-40. https://doi.org/10.14419/g3wyqn50